NIH PET and SPECT Ligands Guide
Updated 6 official sources
Quick Answer: PAR-25-036 expired on May 8, 2026; its last listed due date was May 7, 2026, and NIH hadn't posted a reissue as of October 9, 2026.
Full answer and how we checked it
If a reissue appears, eligibility will likely turn on the same 7 checks: CNS-disorder relevance, unmet target need, ligand-development rationale, imaging feasibility, biomarker role, clinical-trial boundary, and R01 readiness.
Who this is for: CNS biomarker teams, PET and SPECT imaging researchers, tracer-development groups, drug-discovery teams, translational neuroscience investigators, and sponsored-research offices deciding whether PAR-25-036 is the right NIH route.
Data note: This guide uses the official NIH PAR-25-036 NOFO, Grants.gov listing 357006, NIH clinical-trial policy pages, Grants.gov records of earlier versions, and NIH RePORTER award records, rechecked October 9, 2026.
In this guide
- 7 PAR-25-036 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- Where This NOFO Stands Now
- What the NOFO Asked Reviewers to Weigh
- What Funded Projects Looked Like
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This Proposal Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day PET/SPECT Ligand Readiness Plan
- 6 Final Research Checks Before Submission
- 4 Decision Questions Before You Commit
- 3 Last-Mile Checks For Imaging Teams
- Sources
Quick Facts
- Agency
- HHS
- Last deadline
- May 7, 2026 (passed)
- Status
- Closed
Assistance Listing 93.866: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.866, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 10,364
- Avg Award (whole listing)
- $3,365,037
- Median Award (whole listing)
- $1,781,166
- Total Funding (FY2024, whole listing)
- $3.8B
- YoY Funding Trend
- -0.1%
Data last verified: May 19, 2026
According to NIH PAR-25-036 (opens in a new tab), this NOFO supports development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders. NIH listed the activity code as R01 and marked clinical trials as optional. The notice now carries NIH's "This notice has expired" banner.
This route is not for every imaging study. The core question is whether the project advances a PET or SPECT ligand as a meaningful CNS biomarker, not whether imaging is useful somewhere inside the project.
Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI clinical trial pilot guide, NINDS U01 renewal guide, and the Grantsights grant database.
7 PAR-25-036 Eligibility Stop Checks
| Stop check | Strong PAR-25-036 signal | Red flag |
|---|---|---|
| CNS relevance | CNS disorder biology is central | Target is not CNS-relevant |
| Target need | Human PET tracer need is clear | Existing ligand is enough |
| Ligand rationale | Chemistry, binding, and specificity path are credible | Ligand plan is speculative |
| Imaging feasibility | PET or SPECT method is justified | Imaging is routine support |
| Biomarker role | Drug discovery or pathophysiology use case is specific | Biomarker endpoint is vague |
| Clinical-trial boundary | Optional trial status is handled correctly | Trial work is hidden or unclear |
| R01 readiness | Multi-year research plan is mature | Better fit is R21, R61/R33, or tool-development route |
Imaging proposals can weaken when the tracer is treated like a service component. In this NOFO, the ligand-biomarker story needs to be the point.
5 Source Facts Applicants Should Know
According to NIH, PAR-25-036 supports PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders.
According to NIH, interested parties are encouraged to contact the appropriate NIH Program Officer to discuss the perceived level of need for a particular human PET tracer. NIH marks the NOFO as R01 Clinical Trial Optional.
According to USAspending.gov (opens in a new tab) data, assistance listing 93.866 had about $3.83B in FY2024 obligations across 10,364 awards active that year.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-036 |
| Activity code | R01 |
| Clinical trial status | Clinical Trial Optional |
| Status | Expired May 8, 2026; no reissue posted as of Oct 9, 2026 |
| Participating ICs | NIMH and NIA |
| Budget and period | Not capped; up to 5 years |
| Live listing | Grants.gov listing 357006 |
Where This NOFO Stands Now
Grants.gov search records (opens in a new tab) show this program has been reissued under new numbers repeatedly since 2006: PA-06-461 through PA-06-463, PAR-10-024, PAR-13-158, PAR-16-266, PAR-18-227, PAR-20-037 and PAR-20-038, PAR-23-164 and PAR-23-165, and then PAR-25-036. That history suggests NIMH and NIA may reissue it again, but no forecast or new NOFO was listed on October 9, 2026, so treat that as a possibility, not a date.
Until then, a CNS radiotracer project can still go to an open parent announcement. The NIH Parent R01, Clinical Trial Not Allowed (PA-25-301) (opens in a new tab) runs through January 7, 2028, and PA-25-305 covers R01s that require a clinical trial. Standard dates apply: new R01s are due February 5, June 5, and October 5, and resubmissions March 5, July 5, and November 5. The parent route loses the NOFO's targeted language, so email the NIMH or NIA program officer named in PAR-25-036 about fit and institute interest before you write. The NIH R01 research project grant guide covers parent R01 mechanics, and the R01 vs R21 vs R03 comparison helps if the tracer work is still early enough for a 2-year exploratory grant.
What the NOFO Asked Reviewers to Weigh
PAR-25-036 used NIH's simplified review framework with NOFO-specific additions, and those are the best guide to what a reissue will ask:
- Importance: reviewers evaluate the justification for a radiotracer for the target or cellular process, its intended uses, and the questions it would let the field answer.
- Rigor and feasibility: how well the application shows the target can be detected in the brain regions of interest, the desired tracer properties, and the plan and timeline to reach them.
- Expertise and resources: whether a biological collaborator or advisor who'd actually use the tracer is involved in choosing the target.
Two scope rules sit in the NOFO text. A feasibility assessment, such as target density and affinity in post-mortem human brain or a published reference for it, had to exist before submitting a tracer discovery project. And NIH flagged limited interest in another tracer for a target class already in its CNS Radiotracer Table unless you make a compelling case. NIH also named agonist and allosteric-modulator ligands, plus tracers for neuroinflammation, synaptic integrity, and mitochondrial function, as of particular interest, and it encouraged pharmaceutical scientists to join as PIs or key personnel.
What Funded Projects Looked Like
Grantsights checked the NOFO numbers against NIH RePORTER (opens in a new tab) records pulled October 9, 2026. Grantsights analysis of those records found few awards under these numbers. A real-world example: under PAR-25-036, NIA funded St. Jude Children's Research Hospital's pro-drug imaging agents to detect neuroinflammation in Alzheimer's disease (1R01AG093113-01A1, $758,781 in FY2026). Under the earlier PAR-23-165, NIMH funded McLean Hospital's D2high receptor imaging project (R01MH134074), which received $666,559 in FY2026, its third year. Both were funded on a resubmission (A1), and both target a defined CNS process. Under PAR-20-038, NIA funded a first-in-human evaluation of an astrocytic glutamate transporter tracer at UC San Francisco (1R01AG072743-01A1, $784,058 in FY2022) and Memorial Sloan Kettering's [18F]-PU-AD epichaperome PET probe as an RF1 (1RF1AG071805-01A1, $3,589,781). The common thread is a named molecular target with a clear disease question. A thin award record also means a program officer conversation before writing matters more, not less: with so few slots, a project the institute doesn't see as a priority target is a weak bet even if the chemistry is strong.
What NIH Doesn't Tell You
Within 21 days, answer 4 practical questions. First, ligand need must be argued, not assumed. If a field already has adequate human tracers, the team needs a sharper rationale.
Second, the path from chemistry to biomarker should be concrete. A team developing a CNS PET ligand with a target-engagement use in drug discovery has a clearer route than a team using PET as an exploratory add-on.
Third, clinical-trial optional does not mean trial details can be vague. If human studies are included, the application needs human-subjects, statistical, safety, and imaging-readiness detail.
Fourth, NIMH asked for Common Data Elements in mental health human subjects research and budgeted data submission to the NIMH Data Archive, so human imaging projects routed to NIMH should plan for that cost.
6 Evidence Assets That Make This Proposal Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the target-need memo. Explain the CNS target, disorder context, current tracer gap, and why a new or improved ligand matters.
Asset 2 is the ligand-readiness plan. Include chemistry, binding, selectivity, metabolism, dosimetry when relevant, and species translation.
Asset 3 is the biomarker-use memo. State whether the ligand supports drug discovery, target engagement, disease biology, stratification, progression, or treatment-response work.
Asset 4 is the imaging protocol plan. Include PET or SPECT method, acquisition, quantification, reproducibility, scanner or site plan, and analysis.
Asset 5 is the clinical-trial boundary memo. State whether the proposal includes an NIH-defined clinical trial and why.
Asset 6 is the route memo. Compare PAR-25-036 with R21, R61/R33, device or assay development routes, NINDS, NIA, NIMH, NIDA, NHLBI, and private translational funding.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-036 reissue | PET/SPECT ligand biomarker project is mature | Watch for a new number |
| Parent R01 (PA-25-301) | Project is ready now | Open through Jan 7, 2028 |
| R21 | Early feasibility dominates | Smaller route may fit |
| R61/R33 | Milestone-driven development dominates | Phased route may fit |
| Clinical trial NOFO | Trial endpoint dominates | Trial route may fit |
| Private or pharma route | Target-engagement assay is product-facing | Non-NIH route may fit |
Warning: if the ligand could be removed and the science still works, don't start with PAR-25-036.
6 Bad-Fit Signals
First, the target is not tied to CNS disorders. Second, ligand need is not clear. Third, PET or SPECT is routine support.
Fourth, the proposal lacks preclinical or human feasibility logic. Fifth, clinical-trial status is unclear. Sixth, the project is too early for an R01.
These signals are route risks.
21-Day PET/SPECT Ligand Readiness Plan
Days 1 through 3 should confirm target need, CNS-disorder relevance, clinical-trial status, and route alternatives. Days 4 through 7 should write the target-need and ligand-readiness memos.
Days 8 through 12 should build biomarker-use and imaging-protocol plans. Days 13 through 16 should check human-subjects, trial boundary, budget, team expertise, and program officer questions. Days 17 through 21 should complete NIH application checks and route proof.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final checks. Check 1 is the NIH PAR-25-036 NOFO (opens in a new tab). Check 2 is NIH clinical trial policy (opens in a new tab). Check 3 is CNS target need. Check 4 is ligand feasibility. Check 5 is biomarker use. Check 6 is clinical-trial boundary.
You're ready when the team can state the CNS target, ligand gap, imaging method, biomarker use, clinical-trial status, and route reason in 6 direct sentences.
4 Decision Questions Before You Commit
Within 21 days, ask 4 decision questions. Question 1: "What CNS target needs a PET or SPECT ligand?" Question 2: "What biomarker decision will the ligand support?" Question 3: "Is a clinical trial included?" Question 4: "Is the project mature enough for R01 review?"
If question 1 is weak, redirect before the team writes aims.
3 Last-Mile Checks For Imaging Teams
Within 21 days, run 3 last-mile checks. Check 1 is target proof. Check 2 is ligand proof. Check 3 is biomarker proof.
If those checks are weak, a program officer conversation may save the route. A final note for applicants: write the PAR-25-036 fit sentence before the Specific Aims page. In 2 sentences, state the CNS target, ligand gap, imaging method, biomarker use, and reason this R01 is the best route.
Sources
Largest awards active in FY2024
One row per recipient, its largest award | 10,364 Assistance Listing records | Avg: $3.4M
University of California, Los Angeles
CA
Regents of the University of Michigan
MI
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Frequently Asked Questions
What does PAR-25-036 support?
It supported development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders. NIH lists it as expired on May 8, 2026, and no reissue was posted as of October 9, 2026.
What activity code applies?
NIH listed R01 for this NOFO, with NIMH and NIA participating. Budgets weren't capped, and project periods could run up to 5 years.
Are clinical trials allowed?
Yes. NIH marks the NOFO as Clinical Trial Optional.
What should teams prove before applying?
Teams should prove target need, ligand rationale, imaging feasibility, biomarker use case, CNS-disorder relevance, and translational path.
Who should skip this route?
Skip it when the ligand is not tied to a CNS target or biomarker question, or when the project is only routine imaging support.
Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
NIH Grants 2026: R01, K Awards, R21, R35, SBIR
Compare NIH R01, K awards, R21, R03, R35, SBIR/STTR, success rates, deadlines, and program pages before choosing a route.
NIH Clinical Center U01 Eligibility Guide
NIH Clinical Center U01 guide: 8 checks for PAR-26-116, intramural collaboration, Clinical Center use, $500K direct-cost cap, and LOS prep.
NIH Emergency Competitive Revision Guide
PA-24-201 guide: NIH emergency competitive revision eligibility, active parent award rule, Emergency NOSI requirement, disaster basis, and route checks.
NIH K24 Midcareer Investigator Award Guide
NIH K24 midcareer investigator award eligibility guide for PA-24-188, 25% to 50% effort, mentoring proof, trial limits, and route choice.
Latin America health disparities R01 eligibility Guide
NIMHD ended PAR-25-342 early on June 3, 2026. What the Latin America R01 covered, 8 fit checks, and where to look for current NIMHD funding.
NIH NextTech R18 Guide 2026: Eligibility
NIH NextTech R18 guide for 2026: eligibility, $6M program funding, BRAIN and HEAL fit, first-in-human readiness, and trial limits.